Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evolent Health Affirms Q3 Sales Guidance of $460.000M-$480.000M vs $473.745M Est

Author: Benzinga Newsdesk | September 23, 2025 04:36pm
Evolent Health (NYSE:EVH) affirms Q3 sales outlook from $460.000 million-$480.000 million to $460.000 million-$480.000 million vs $473.745 million estimate.

Posted In: EVH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist